TNF and breast cancer: Moreover, MUC4 expression in cancer specimens would help select the subgroup of HER2-positive breast cancer patients that benefit from the combination of anti-TNFα therapies with the standard treatments, as we previously demonstrated in HER2-positive breast cancer.